Mergers & Acquisitions in Pharma Industry
PROJECT REPORT
ON
A Successful International Merger in India:
GlaxoSmithKline pharmaceutical industry
Table of Contents:
Declaration
Abstract Part I –Introduction Research Objective and justifications
Report Outline Part-II Industry Description GSK-The Big Picture Factors for success in India References Part-III Literature review Chapter One –Merger: An Introduction 1.1 Introduction 1.2 The Main Idea
1.3 Types of Merger 1.4 Reasons for International M&A Chapter Summary References Chapter Two-Nature of Indian pharmaceutical Industry 2.1 Introduction 2.2 Nature of Indian Pharmaceutical Industry
2.2.1 Industry Scenario 2.2.2 Market Scenario ((Projected Pharmaceutical Market, 2004-2009)) 2.2.3 New Product Launches underlie market growth 2.2.5 Key Opportunities 2.2.6 FDI in Indian pharma 2.2.7 Strategy and Trends 2.2.8 Research and Development 2.2.9 SWOT Analysis 2.2.10 Mergers and Acquisitions in Pharma 2.2.11 Good Opportunities for ‘big pharma’ References Chapter Three-Merger between Glaxo Wellcome Smithkline Beecham 3.1 Introduction 3.2 Merger rationale 3.2.1 Rapid advances in Science and Technology 3.2.2 The growing importance of marketing power
3.2.3 The emergence of patients as consumers 3.3 Merger Benefits 3.3.1 Short term growth 3.3.2 Medium term growth 3.3.3 Long term growth
ON
A Successful International Merger in India:
GlaxoSmithKline pharmaceutical industry
Table of Contents:
Declaration
Abstract Part I –Introduction Research Objective and justifications
Report Outline Part-II Industry Description GSK-The Big Picture Factors for success in India References Part-III Literature review Chapter One –Merger: An Introduction 1.1 Introduction 1.2 The Main Idea
1.3 Types of Merger 1.4 Reasons for International M&A Chapter Summary References Chapter Two-Nature of Indian pharmaceutical Industry 2.1 Introduction 2.2 Nature of Indian Pharmaceutical Industry
2.2.1 Industry Scenario 2.2.2 Market Scenario ((Projected Pharmaceutical Market, 2004-2009)) 2.2.3 New Product Launches underlie market growth 2.2.5 Key Opportunities 2.2.6 FDI in Indian pharma 2.2.7 Strategy and Trends 2.2.8 Research and Development 2.2.9 SWOT Analysis 2.2.10 Mergers and Acquisitions in Pharma 2.2.11 Good Opportunities for ‘big pharma’ References Chapter Three-Merger between Glaxo Wellcome Smithkline Beecham 3.1 Introduction 3.2 Merger rationale 3.2.1 Rapid advances in Science and Technology 3.2.2 The growing importance of marketing power
3.2.3 The emergence of patients as consumers 3.3 Merger Benefits 3.3.1 Short term growth 3.3.2 Medium term growth 3.3.3 Long term growth
References: http://www.gsk-india.com/investorsrelations/financial results. Asp GlaxoSmithKline (GSK) (2001) Merger Document Publication, GSK, India GlaxoSmithKline (GSK) (2001) Annual Report-2001, GSK, India GlaxoSmithKline (GSK) (2002) Annual Report-2002, GSK, India GlaxoSmithKline (GSK) (2003) Annual Report-2003, GSK, India GlaxoSmithKline (GSK) (2004) Annual Report-2004, GSK, India GlaxoSmithKline (GSK) (2005) Annual Report-2005, GSK, India GlaxoSmithKline (GSK) (2005) Annual Report-2009, GSK, India GlaxoSmithKline (GSK) (2005) Annual Report-2010, GSK, India 7.3.2 Schemes of arrangement: The scheme is a statutory procedure under section 425 of the Companies Act 1985 (1985 Act) which allows a company to make a compromise or arrangement with its shareholders or a class of its shareholders or creditors B Court approval. -- The scheme must be sanctioned by the court. The scheme does not become effective until a copy of the court order is delivered to the Registrar of Companies for registration (section 425(3), 1985 Act).